News headlines about Alexion Pharmaceuticals (NASDAQ:ALXN) have been trending positive on Thursday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a news sentiment score of 0.26 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.1455424443563 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Alexion Pharmaceuticals (ALXN) Downgraded to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Alexion loses two executives amid Boston relocation (finance.yahoo.com)
- SunTrust Banks Reiterates “$172.00” Price Target for Alexion Pharmaceuticals (ALXN) (americanbankingnews.com)
- Alexion Pharmaceuticals (ALXN) Price Target Cut to $170.00 by Analysts at Citigroup (americanbankingnews.com)
- Alexion Pharmaceuticals (ALXN) Given a $161.00 Price Target at Deutsche Bank (americanbankingnews.com)
Several brokerages have weighed in on ALXN. Evercore ISI raised shares of Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research note on Monday, February 5th. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday. Citigroup lowered their target price on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a research note on Friday, February 9th. Leerink Swann reduced their price target on shares of Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Finally, BMO Capital Markets increased their price target on shares of Alexion Pharmaceuticals from $177.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and twenty-one have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $152.77.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.09 by $0.39. The firm had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 earnings per share. equities analysts forecast that Alexion Pharmaceuticals will post 6.13 EPS for the current year.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the sale, the chief executive officer now owns 36,172 shares of the company’s stock, valued at $4,399,600.36. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Paul J. Clancy sold 6,079 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $707,048.49. Following the sale, the chief financial officer now directly owns 95,093 shares in the company, valued at approximately $11,060,266.83. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,930 shares of company stock worth $3,378,199. 4.35% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://weekherald.com/2018/02/15/alexion-pharmaceuticals-alxn-given-daily-coverage-optimism-score-of-0-26.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.